Pfizer lowers COVID-19 vaccine doses for younger kids in clinical trial
Pfizer said it has selected lower dosages of its COVID-19 vaccine for Phase 2/3 portions of its clinical trial involving kids younger than 11 than the volume given to shot recipients ages 12 and older.